Member Info for COLDWATER

I think it highly unlikely there will be any news of a deal or suchlike, as invariably these things "leak" and we would have seen large scale buying, and a boost to the SP.

Far more likely a plan to raise funds.

I've been away for over a week, but nothing seems to have changed .

I was an Auditor for over 20 years, and I very much doubt that the delay is due to the accounts themselves. All auditors ensure they complete the process well before any scheduled AGM, to give the BOD time to understand and react to the results. So it must be something else, and funding is the most likely issue.

The latest appointments are, in my view, to address that specifically.

We shall see......

I believe this week’s welcome rise is fragile and may not hold without firm news of financial support forthcoming.

The recent clinical trial review seems to have been held to soften us up for the bad news coming next week.

Given the volume of purchases by IIs over early spring, and the continuous fall in the share price, the sellers must have been principally Heights?

The apparent excellence in the science developed by Avacta has been badly let down by woeful financial and commercial management.

I really do fear the worst now.

And so what?

The Company goes bust and the liquidator sells it off for peanuts?

I would slaver at a T/O offer of £1 per share.

It hasnt started yet.

Waiting for someone - liquidiser?

Well, I do hope you guys are right this time.

We seem to have been here many times before in the past 4 years or so, with mostly disappointing consequences. Each time I bought some more, and each time sat on more losses – with the occasional bounce.

What could they possibly say? From the heady days of3/4 years ago, where everything seemed possible, it’s been a long descent. It seems increasingly clear that there is no appetite from BP for this company.

The scientists in the Company have been enjoying themselves with their experiments at our expense.

Blimey ICE.

Some sensible coherent analysis!

Can someone please translate this into simple English please?

So why doesn't "the market" share those views?

I still don't see why there has to be a takeover. I doubt CC wants to give this science up. I still believe it will be a case of licensing the drug(s) and the Company gets a good share of the sales revenues.

I think McNuff has this right.

There is little doubt that the science has been successful, although very slowly over many years. The hopes for early FDA approval haven’t been realised, and although it is possible that current trials will eventually show how effective the drug(s) are, the harsh reality of the business world won’t wait. Bills have to be paid, and “the market” is saying it doesn’t think the Company will make it alone.

So at some stage, the Company will either –

A – fall victim to a low offer, whereby the science and key staff will be transferred to a BP

Or B – sell the science off and continue development of new projects.

Either way, I see poor prospects for PIs.

" I'm happy to wait for those returns because the later they wait the more we're going to get."

And the more you're going to pay....

I have decided to join this board to try to introduce some rational thought to what is an increasingly polarised discussion about how much the Company’s shares are really worth in the medium term.

I have read the board for about 4 years, and used to enjoy reading what information others had gleaned from various sources, but that seems to have almost ceased.

The biggest issue currently seems to be what value to place on the Company. There is an assumption that at some stage, if the science stands up to peer review, the Company will be taken over. Why? Is my question.

Some of the values bandied about have been from £5-200 per share, well in excess of the current market price. At £20 per share I would become a millionaire and I suspect others here would also. Do you seriously think the Large Pharmaceutical companies ( LPs) are going to give that kind of largesse to shareholders?

If the trial results prove successful, surely Avacta will grant licences to the LPs to manufacture and distribute the drugs. Avacta then gains significant revenues to enable it to continue its research (which I believe is what the current BOD wants). Of course, the value of the Company will increase, and the market value as well, but not to anything like the figures suggested. Yes, if this happens, there will be dividends, and Avacta continues as a research organisation, but the large funds don’t come to us.